The DREAMM-2 Trial

Video

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      4 experts are featured in this series.
      Role of Bridging Therapy for CAR-T Patients
      4 experts are featured in this series.
      Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
      4 experts are featured in this series.
      Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
      4 experts are featured in this series.
      Overview of Process of CAR-T Therapy
      Related Content
      Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

      Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma

      Roman Fabbricatore
      March 25th 2025
      Article

      Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

      Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma

      Roman Fabbricatore
      March 21st 2025
      Article

      Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Tim Cortese
      March 14th 2025
      Article

      Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      ONCOLOGY Staff
      March 9th 2025
      Article

      A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.